Clinical usefulness of random biopsies in diagnosis and treatment of non-muscle invasive bladder cancer: Systematic review and meta-analysis

Subiela, José Daniel; Palou, Joan; Esquinas, Cristina; Gómez, J M Fernández; Faba, Ó. Rodríguez

doi:10.1016/j.acuroe.2018.04.002

Cited by 7 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study by Hara et al including 173 patients, up to 59% of high-risk patients with normal-appearing cystoscopy had confirmed CIS in biopsy specimen and a significant association between a positive urine cytology and detection of CIS through random bladder biopsies was demonstrated 193 . Urine cytology had a sensitivity of 87.1% and specificity of 63% for detecting CIS in a recent meta-analysis by Subiella et al (LE 2), meaning that 37% of patients with negative urine cytology samples might in fact harbour CIS 96 . In this same study, the overall detection rate of CIS through random bladder biopsies of normal appearing mucosa was 17.4%, which increased to 57.3% when urine cytology was positive 96 .…”

Section: Random Bladder Biopsiesmentioning

confidence: 98%

“…Urine cytology had a sensitivity of 87.1% and specificity of 63% for detecting CIS in a recent meta-analysis by Subiella et al (LE 2), meaning that 37% of patients with negative urine cytology samples might in fact harbour CIS 96 . In this same study, the overall detection rate of CIS through random bladder biopsies of normal appearing mucosa was 17.4%, which increased to 57.3% when urine cytology was positive 96 . In a setting of normal cystoscopy and normal upper urinary tract imaging, random bladder biopsies should be performed if urine cytology is positive (LE 2; strong recommendation).…”

Section: Random Bladder Biopsiesmentioning

confidence: 98%

“…Concomitant CIS is diagnosed in up to 19% of NMIBC cases 96 . This entity is described as a flat lesion confined to the bladder mucosa and is HG by definition 97 .…”

Section: Carcinoma In Situmentioning

confidence: 99%

See 2 more Smart Citations

Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer

Bhindi

Kool

Kulkarni

et al. 2021

CUAJ

View full text Add to dashboard Cite

Section: Random Bladder Biopsiesmentioning

confidence: 98%

Section: Random Bladder Biopsiesmentioning

confidence: 98%

See 1 more Smart Citation

Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer

Bhindi

Kool

Kulkarni

et al. 2021

CUAJ

View full text Add to dashboard Cite

“…First, CIS is a high-risk kind of NMIBC confined to the mucosa, which can easily be confused with inflammatory lesions due to its similar structural appearance under WLC. A recent systematic review was conducted to analyze the results of random bladder biopsy in >10 000 patients with NMIBC, and the total incidence of CIS was 17.35% ( 61 ). Moreover, the rate of concurrent CIS reach up to 50% in patients with high-grade or sessile tumors ( 61 , 62 ).…”

Section: Application Of Optical Molecular Imaging In the Management Omentioning

confidence: 99%

“…A recent systematic review was conducted to analyze the results of random bladder biopsy in >10 000 patients with NMIBC, and the total incidence of CIS was 17.35% ( 61 ). Moreover, the rate of concurrent CIS reach up to 50% in patients with high-grade or sessile tumors ( 61 , 62 ). Second, small or occult tumors, some of which may be high-grade or invasive lesions, are difficulty to detect ( 63 ).…”

Section: Application Of Optical Molecular Imaging In the Management Omentioning

confidence: 99%

En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

Although transurethral resection of bladder tumor is the golden standard for the treatment of non-muscle invasive bladder cancer, this surgical procedure still has some serious drawbacks. For example, piecemeal resection of tumor tissue results in exfoliated tumor cells dissemination and implantation, and fragmented tumor specimens make it difficult for pathologists to accurately assess the pathological stage and histologic grade. En bloc tumor resection follows the basic principle of oncological surgery and provides an intact tumor specimen containing detrusor muscle for pathologists to make accurate histopathological assessment. However, there is no robust clinical evidence that en bloc tumor resection is superior to conventional resection in terms of oncological outcomes. Considering the high recurrence rate, small or occult tumor lesions may be overlooked and incomplete tumor resection may occur during white light cystoscopy-assisted transurethral resection. Molecular fluorescent tracers have the ability to bind tumor cells with high sensitivity and specificity. Optical molecular imaging mediated by it can detect small or occult malignant lesions while minimizing the occurrence of false-positive results. Meanwhile, optical molecular imaging can provide dynamic and real-time image guidance in the surgical procedure, which helps urologists to accurately determine the boundary and depth of tumor invasion, so as to perform complete and high-quality transurethral tumor resection. Integrating the advantages of these two technologies, optical molecular imaging-assisted en bloc tumor resection shows the potential to improve the positive detection rate of small or occult tumor lesions and the quality of transurethral resection, resulting in high recurrence-free and progression-free survival rates.

show abstract

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

Kamat,

Apolo,

Babjuk

et al. 2023

JCO

View full text Add to dashboard Cite

PURPOSE There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel. METHODS Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually). RESULTS The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text. CONCLUSION These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

show abstract

Clinical usefulness of random biopsies in diagnosis and treatment of non-muscle invasive bladder cancer: Systematic review and meta-analysis

Cited by 7 publications

References 47 publications

Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer

Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer

En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

Contact Info

Product

Resources

About